CymaBay Therapeutics Inc. (CBAY)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.
The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target.
The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
7575 Gateway Blvd Ste 110
Newark, California 94560-1194
|Phone||510 293 8800|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Sujal A. Shah||President, Chief Executive Officer and Director|
|Dr. Dennis D. Kim M.B.A., M.D., MBA||Chief Medical Officer|
|Lewis J. Stuart B.A., BA, M.B.A., MBA||Chief Commercial Officer|
|Daniel Menold||Vice President of Finance|
|Dr. Charles A. McWherter Ph.D.||Senior Vice President and Chief Scientific Officer|
|Paul T. Quinlan||General Counsel, Chief Compliance Officer and Corporate Secretary|
|Ken Boehm||Senior Vice President of Human Resources|
|Patrick J. O'Mara||Senior Vice President of Business Development|
|Dr. Robert L. Martin||Senior Vice President of Manufacturing and Nonclinical Development|
|Klara A. Dickinson-Eason||Chief Regulatory and Quality Assurance Officer|
Latest SEC Filings
|Jun 14, 2022||8-K||Current report|
|Jun 7, 2022||4||Statement of changes in beneficial ownership of securities|
|May 12, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Apr 26, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 26, 2022||DEF 14A||Other definitive proxy statements|
|Apr 19, 2022||8-K/A||Current report|
|Mar 21, 2022||4||Statement of changes in beneficial ownership of securities|
|Mar 21, 2022||3||Initial statement of beneficial ownership of securities|
|Mar 17, 2022||8-K||Current report|
|Mar 17, 2022||S-8||Securities to be offered to employees in employee benefit plans|